EC Number |
Application |
Reference |
---|
3.2.1.113 | diagnostics |
MAN1C1 may be a useful prognostic biomarker and potential therapeutic target in clear cell renal cell carcinoma, with the potential to lead to better outcomes for patients with these poor prognosis malignancies |
751168 |
3.2.1.113 | drug development |
development of anti-cancer therapies |
677921 |
3.2.1.113 | medicine |
the class I alpha-mannosidases can be used as drug targets to inhibit the demannosylation of HBV, thereby improving the binding of the virus to DC-SIGN and disrupting the immune tolerance to prevent and treat viral infection |
752329 |
3.2.1.113 | pharmacology |
in triple KO (MAN1A1, MAN1A2, and MAN1B1) cells, Man9GlcNAc2 and Man8GlcNAc2 are the major N-glycan structures. The N-glycan structures on recombinant proteins expressed in triple KO cells are simplified and changed from complex types to high-mannose types at the protein level. The triple KO HEK293 cells are suitable for producing recombinant proteins, including lysosomal enzymes with high-mannose-type N-glycans. This approach should accelerate the production of biopharmaceutical proteins with homogenous glycans |
751118 |